# **CLINICAL** INQUIRIES

brought to you by 🗓 CORE

Family Physicians Inquiries Network

From the

# Which lifestyle interventions effectively lower LDL cholesterol?

# **Evidence-based answer**

Counseling, weight loss, exercise, and drinking alcohol all effectively lower low-density lipoprotein cholesterol (LDL-C). Specifically, one to 2 daily drinks of alcohol lowers LDL-C, if consumed regularly for more than 4 weeks (strength of recommendation [SOR]: **A**, based on consistent results of multiple randomized controlled trials [RCTs]).

Counseling by physicians, dieticians, or pharmacists is effective at increasing patient compliance with medications, thereby lowering LDL-C (SOR: **C**, good evidence that intervention lowers LDL-C, insufficient to prove that it reduces mortality/morbidity).

Weight loss has been associated with reductions in LDL-C. However,

## **Clinical commentary**

# Consider patient preference when discussing lifestyle modification

Therapeutic lifestyle changes are the initial treatment of choice for reduction of cardiac risk factors, but both patients and physicians often see these modifications as confusing and difficult to achieve. A recent year-long study on different diets concluded that dietary adherence is more important than a specific type of diet for weight loss and reduction of cardiac risk factors.<sup>1</sup> Another recent study reports no

other factors-including degree of caloric restriction, drug intervention, and diet composition-may play a more significant role than weight loss alone (SOR: A, based on a meta-analysis and consistent results of RCTs). 01 Exercise significantly lowers LDL-C (SOR: A, based on meta-analyses and consistent results of RCTs). Smoking cessation may have a beneficial effect (SOR: B, based on inconsistent results from RCTs that it lowers LDL-C). Exercisebased alternative practices (yoga and tai chi) lower LDL, and meditation may have a beneficial effect (SOR: C, moderate evidence that intervention lowers LDL, insufficient evidence to prove that it reduces mortality/morbidity).

difference in weight loss among diets, based on different exercise duration and intensities over 1 year in a group of sedentary and overweight women.<sup>2</sup> Therefore, family physicians should consider culture, patient preference, and practical issues such as cost and availability, when discussing therapeutic lifestyle modification with patients.

> Vincent Lo, MD San Joaquin Family Medicine Residency, French Camp, Calif

Elizabeth Powers, MD, John Saultz, MD, and Andrew Hamilton, MLS Oregon Health and Sciences University, Portland

## FAST TRACK

Weight loss lowers LDL-C, although some studies suggest it may be short-term

CONTINUED

# TABLE

## A- and B-level evidence points to effectiveness of lifestyle interventions

LIFESTYLE INTERVENTION	MAGNITUDE OF EFFECT ON LDL-C	% REDUCTION LDL-C	DATA SOURCES	SOR
Alcohol	4–10 mg/dL	4%–8%	4 RCTs	А
Counseling	0–58 mg/dL	0%–33%	15 RCTs, 8 CTs	А
Exercise	3–16 mg/dL	2.5%–4%	5 meta-analysis	А
Meditation	0–28 mg/dL	0%–19%	3 RCTs	В
Smoking	0–5 mg/dL	0%–4%	2 RCTs	В
Weight loss: – diet, exercise, supplements – drug therapy	0–42 mg/dL 10–31 mg/dL	0%–22% 11%–32%	28 RCTs, 14 CTs, 1 meta-analysis 4 RCTs, 2 CTs	A
Yoga/tai chi	20–26 mg/dL	15%–20%	2 RCTs, 1 CT	А

LDL-C, low-density lipoprotein cholesterol; SOR, strength of recommendation;

RCT, randomized controlled trial; CT, clinical trials.

SOR: A, good evidence that intervention lowers LDL. SOR: B, moderate evidence.

## Evidence summary

Elevated LDL-C is an independent risk factor for coronary heart disease (CHD),<sup>3</sup> the leading cause of death in the US.<sup>4</sup> Lowering LDL-C by 60 mg/dL reduces CHD events by 50% after 2 years.<sup>5</sup> Although medications successfully lower LDL-C and decrease CHD risk, therapeutic lifestyle changes remain the initial therapy for most adult patients.<sup>3,6</sup>

Our search located evidence about alcohol consumption, counseling, exercise, weight loss, alternative lifestyle measures, and smoking cessation. The **TABLE** summarizes the evidence for each.

## 1 to 2 drinks daily reduced LDL-C

One 5-year-long cohort study (N=933) showed that alcohol was associated with LDL-C reduction in a dose-dependent manner.<sup>7</sup> Two crossover trials (4–6 weeks in duration) conducted among heavy drinkers showed that LDL-C increased when alcohol intake decreased. Two randomized crossover trials (8–12 weeks in duration) found a statistically significant decrease in LDL-C with consumption of 1 to 2 drinks daily.

# Counseling improves medication adherence

An RCT (N=167) with 8 years of follow-up found that patient education and counseling effectively improved medication adherence.<sup>8</sup> Another RCT (N=1162) lasting 1 year, however, found that nutrition counseling by primary care physicians resulted in no significant change in LDL-C compared with usual care.<sup>9</sup>

Studies focused on enhancing dietary compliance did not find consistent postintervention improvement. Greater medication adherence or improved dietary compliance did result in consistent significant improvements in LDL-C.

# Exercise lowers LDL; weight loss a factor

Aerobic exercise effectively lowers LDL-C. This reduction is enhanced by weight loss and diet and mitigated by weight gain.<sup>10</sup> An analysis of 4 RCTs showed that LDL-C also decreased with resistance training.

A higher body-mass index is associated with higher LDL-C. However, the effect of weight loss *per se* on LDL-C remains unclear. Multiple short-term studies have found that a modest amount of

# FAST TRACK 2 clinical trials

found that LDL decreased significantly with 1 to 2 alcohol drinks per day weight loss (5%–10%) is associated with a significant reduction in LDL-C.<sup>11</sup> A meta-analysis found a 0.8 mg/dL LDL-C decrease for every kg of weight lost. Longterm follow-up, however, showed that LDL-C returned to baseline even when weight loss was maintained. Eight clinical trials failed to demonstrate a reduction in LDL-C postintervention with up to 10 kg of weight loss. Studies using weight-loss drugs (Sibutramine, Orlistat) found more significant weight loss during treatment, along with greater decrease in LDL-C, when compared with studies using only lifestyle modifications.

## Other measures have mixed results

High-quality RCTs (N=267) with yoga or tai chi as the exercise intervention showed a statistically significant decrease in LDL-C over 12 to 14 weeks.<sup>12</sup> Two RCTs investigated the effect of meditation on LDL-C with mixed results. One (N=16) showed a significant decrease in LDL-C over 8 weeks, while a second (N=60) showed no difference in LDL-C. A high-quality RCT (N=91) with a combined intervention (counseling, exercise, and meditation over 1 year) showed a significant decrease in LDL-C.

In cross-sectional surveys, LDL-C does not appear to differ between smokers and nonsmokers. One meta-analysis found a dose-dependent relationship between smoking and LDL-C, with overall LDL-C 1.7% higher for smokers compared with nonsmokers.<sup>13</sup> Two RCTs investigated the effect of smoking cessation on LDL-C with mixed results. One (N=935) showed a decrease in nonfasting LDL-C while a second (N=140) showed no difference in LDL-C.

## **Recommendations from others**

According to ATP III guidelines,<sup>3</sup> all adults with LDL-C above goal should be treated with therapeutic lifestyle changes for primary and secondary prevention of CHD. These include a diet intervention, increased physical activity, and weight loss. Physicians are encouraged to refer patients to a nutritionist. If LDL-C is not at goal after 6 weeks, changes are intensified; physicians should consider pharmacologic therapy if a patient is still unable to attain his or her goal. ACP III guidelines recommend an office visit every 4 to 6 months to monitor adherence.

American Heart Association guidelines recommend that physicians counsel smokers at every office visit to stop smoking. The American College of Cardiology recommends abstinence from alcohol for patients with suspected alcoholic cardiomyopathy. For patients with heart failure from any other cause, alcohol consumption is usually limited to 1 drink per day.

### References

- Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for weight loss and heart disease risk reduction. JAMA 2005; 293:43–53.
- Jakicic JM, Marcus BH, Gallagher KL, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight sedentary women. *JAMA* 2003; 290:1323–1330.
- National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III). Executive Summary. JAMA 2001; 285:2486–2497.
- 4. Deaths: Final Data for 2003. *National Vital Statistics Report* 2003; 54(13). 120 pp. (PHS) 2006–1120.
- Law MR, Wald NJ, Rudnicka AR. Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003; 326:1423.
- Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004; 110:227–239.
- Nakanishi N, Yoshida H, Nakamura K, Kawashimo H, Tatara K. Influence of alcohol intake on risk for increased low-density lipoprotein cholesterol in middle-aged Japanese men. *Alcohol Clin Exp Res* 2001; 25:1046–1050.
- Rachmani R, Slavacheski I, Berla M, Frommer-Shapira R, Ravid M. Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. J Am Soc Nephrol 2005; 16:S22–S26.
- Ockene IS, Hebert JR, Ockene JK, et al. Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). Arch Intern Med 1999; 159:725–731.
- Kelley GA, Kelley KS, Tran ZV. Exercise, lipids, and lipoproteins in older adults: a meta-analysis. *Prev Cardiol* 2005; 8:206–214.
- Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and longterm lipid outcomes: a systematic review. *Obesity Rev* 2004; 5:43–50.
- Tsai JC, Wang WH, Chan P, et al. The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. J Altern Complement Med 2003; 9:747–754.
- Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *Br Med J* 1989; 298:784–788.

## Interested in more references on this topic, broken down by intervention?

Go to www.jfponline.com

### Additional References

### **ALTERNATIVE LIFESTYLE PRACTICES**

Bijlani RL, et al. A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus. *J Alt Complement Med* 2005; 11:267–274.

Tsai JC, et al. The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. *J Alt Complement Med* 2003; 9:747–754.

Mahajan AS, Reddy KS, Sachdeva U. Lipid profile of coronary risk subjects following yogic lifestyle intervention. *Indian Heart J* 1999; 51:37–40.

Carson MA. The impact of a relaxation technique on the lipid profile. *Nurs Res* 1996; 45:271–276.

Jula A, et al. Long-term non-pharmacological treatment for mild to moderate hypertension. *J Intern Med* 1990; 227:413–421.

Carson MA, et al. The effect of a relaxation technique on coronary risk factors. *Behav Med* 1988; 14:71–77.

#### ALCOHOL

Coimbra SR, et al. The action of red wine and purple grape juice on vascular reactivity is independent of plasma lipids in hypercholesterolemic patients. *Brazilian J Med Biol Res* 2005; 38:1339–1347.

Hansen AS, et al. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. *Eur J Clin Nutr* 2005; 59:449–455.

Chrysohoou C, et al. Effects of chronic alcohol consumption on lipid levels, inflammatory and haemostatic factors in the general population: the 'ATTICA' study. *Eur J Cardiovasc Prev Rehabil* 2003; 10:355–361.

Dixon JB, Dixon ME, O'Brien PE. Alcohol consumption in the severely obese: relationship with the metabolic syndrome. *Obes Res* 2002; 10:245–252.

Baer DJ, et al. Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet. *Am J Clin Nutr* 2002; 75:593–599.

Nakanishi N, et al. Influence of alcohol intake on risk for increased low-density lipoprotein cholesterol in middle-aged Japanese men. *Alcohol Clin Exp Res* 2001; 25:1046–1050.

Senault C, et al. Beneficial effects of a moderate consumption of red wine on cellular cholesterol efflux in young men. *Nutr Metab Cardiovasc Dis* 2000; 10:63– 69.

Rakic V, et al. A controlled trial of the effects of pattern of alcohol intake on serum lipid levels in regular drinkers. *Atherosclerosis* 1998; 137:243–252.

Kiechl S, et al. Alcohol consumption and atherosclerosis: what is the relation? Prospective results from the Bruneck Study. *Stroke* 1998; 29:900–907.

Hein HO, Suadicani P, Gyntelberg F. Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. *BMJ* 1996; 312:736–741.

Clevidence BA, et al. Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study. *Arterioscler Thromb Vasc Biol* 1995; 15:179–184. Sharpe PC, et al. Effect of red wine consumption on lipoprotein (a) and other risk factors for atherosclerosis. *QJM* 1995; 88:101–108.

Masarei JR, et al. Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Results from an intervention study in healthy subjects. *Atherosclerosis* 1986; 60:79–87.

#### COUNSELING

Ragucci KR, et al. Effectiveness of pharmacist-administered diabetes mellitus education and management services. *Pharmacotherapy* 2005; 25:1809–1816.

Sallinen J, et al. Effects of strength training and nutritional counseling on metabolic health indicators in aging women. *Can J Appl Physiol* 2005; 30:690–707.

Levetan CS, et al. Impact of computer-generated personalized goals on cholesterol lowering. *Value Health* 2005; 8:639–646.

Rachmani R, et al. Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. *J Am Soc Nephrol* 2005; 16:S22–S26.

Burke LE, et al. Improving adherence to a cholesterollowering diet: a behavioral intervention study. *Patient Educ Couns* 2005; 57:134–142.

Lee SS, Cheung PY, Chow MS. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. *J Clin Pharmacol* 2004; 44:632–639.

Simpson DR, Dixon GB, Bolli P. Effectiveness of multidisciplinary patient counseling in reducing cardiovascular disease risk factors through nonpharmacological intervention: results from the Healthy Heart Program. *Can J Cardiol* 2004; 20:177–186.

Lichtman JH, et al. Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. *Am Heart J* 2004; 147:522–528.

Thomas HD, Maynard C, Wagner GS. Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals. *N C Med J* 2003; 64:263–266.

Reid R, et al. Dietary counseling for dyslipidemia in primary care: results of a randomized trial. *Can J Pract Res* 2002; 63:169–175.

Palomaki A, et al. Effects of preventive group education on the resistance of LDL against oxidation and risk factors for coronary heart disease in bypass surgery patients. *Ann Med* 2002; 34:272–283.

Vale MJ, et al. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world"—randomized controlled trial. *J Clin Epi-demiol* 2002; 55:245–252.

Cabrera-Pivaral CE, et al. Effects of an educational intervention on plasma levels of LDL cholesterol in type 2 diabetics. *Salud Publica Mex* 2001; 43:556–562.

Henkin Y, et al. Dietary treatment of hypercholesterolemia: do dietitians do it better? A randomized, controlled trial. *Am J Med* 2000; 109:549–555.

Faulkner MA, et al. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. *Pharmacotherpy* 2000; 20:410–416.

Hines L. Can low-fat/cholesterol nutrition counseling improve food intake habits and hyperlipidemia of renal

transplant patients? J Ren Nutr 2000; 10:30-35.

Hebert JR, et al. A dietitian-delivered group nutrition program leads to reductions in dietary fat, serum cholesterol, and body weight: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *J Am Diet Assoc* 1999; 99:544–552.

Allison TG, et al. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. *Mayo Clin Proc* 1999; 74:466–473.

Ockene IS, et al. Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyper-lipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *Arch Intern Med* 1999; 159:725-731.

Verges BL, et al. Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention. *J Cardiopulm Rehabil* 1998; 18:408–415.

Keyserling TC, et al. A randomized controlled trial of a physician-directed treatment program for low-income patients with high blood cholesterol: the Southeast Cholesterol Project. *Arch Fam Med* 1997; 6:135–145.

Johnston HJ, et al. Diet modification in lowering plasma cholesterol levels. A randomized trial of three types of intervention. *Med J Aust* 1995; 162:524–526.

Anderson JW, Brinkman VL, Hamilton CC. Weight loss and 2-year follow-up for 80 morbidly obese patients treated with intensive very-low-calorie diet and an education program. *Am J Clin Nutr* 1992; 56:244S–246S.

Rabkin SW, et al. A randomized clinical trial comparing behavior modification and individual counseling in the nutritional therapy of non-insulin-dependent diabetes mellitus: comparison of the effect on blood sugar, body weight, and serum lipids. *Diabetes Care* 1983; 6:50–56.

#### EXERCISE

Kelley GA, Kelley KS, Tran ZV. Exercise, lipids, and lipoproteins in older adults: a meta-analysis. *Prev Cardiol* 2005; 8:206–214.

Kelley GA, Kelley KS, Tran ZV. Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials. *J Womens Health* 2004; 13:1148–1164.

Halbert JA et al. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. *Eur J Clin Nutr* 1999; 53:514–522.

Yu-Poth S, et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999; 69:632–646.

Tran ZV, Weltman A. Differential effects of exercise on serum lipid and lipoprotein levels seen with changes in body weight. A meta-analysis. *JAMA* 1985; 254:919–924.

### SMOKING

Allen SS, Hatsukami D, Gorsline J. Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group. *Prev Med* 1994; 23:190–196.

Hughes K, et al. Relationships between cigarette smoking, blood pressure and serum lipids in the Singapore general population. *Int J Epidemiol* 1993; 22:637–643. Vyssoulis GP, et al. Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. *Am J Cardiol* 1991; 67:987–992.

Cuesta C, et al. Effects of age and cigarette smoking on serum concentrations of lipids and apolipoproteins in a male military population. *Atherosclerosis* 1989; 80:33–39.

Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ* 1989; 298:784–788.

Rabkin SW. Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A controlled clinical trial. *Atherosclerosis* 1984; 53:173–184.

Halfon ST, Green MS, Heiss G. Smoking status and lipid levels in adults of different ethnic origins: the Jerusalem Lipid Research Clinic Program. *Int J Epidemiol* 1984; 13:177–183.

Brischetto CS, et al. Plasma lipid and lipoprotein profiles of cigarette smokers from randomly selected families: enhancement of hyperlipidemia and depression of highdensity lipoprotein. *Am J Cardiol* 1983; 52:675–680.

Sutherland WH, et al. Adiposity, lipids, alcohol consumption, smoking, and gender. *Am J Clin Nutr* 1980; 33: 2581–2587.

Heyden S, et al. The combined effect of smoking and coffee drinking on LDL and HDL cholesterol. *Circulation* 1979; 60:22–25.

### WEIGHT LOSS

Wood RJ, et al. Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL subfraction distribution and size in overweight men. *J Nutr* 2006; 136:384–389.

Lofgren I, et al. Weight loss associated with reduced intake of carbohydrate reduces the atherogenicity of LDL in premenopausal women. *Metabolism* 2005; 54:1133– 1141.

LaHaye SA, et al. Comparison between a low glycemic load diet and a Canada Food Guide diet in cardiac rehabilitation patients in Ontario. *Can J Cardiol* 2005; 21:489–494.

Zemel MB, et al. Dairy augmentation of total and central fat loss in obese subjects. *Int J Obes* 2005; 29:391– 397.

Fernandez ML, et al. Beneficial effects of weight loss on plasma apolipoproteins in post-menopausal women. *J Nutr Biochem* 2004; 15:717–721.

Zaffari D, et al. Effectiveness of diet in hyperlipidemia in renal transplant patients. *Transplant Proc* 2004; 36:889–890.

Erdmann J, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations. *Aliment Parmacol Ther* 2004; 19:1173–1179.

Yancy WS Jr, et al. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. *Ann Int Med* 2004; 140:769–777.

Four popular diets all good for weight loss but not equal for reducing heart disease risk. *SAMJ* 2004; 94:161.

Brook RD, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. *Am J Cardiol* 2004; 93:1012–1016.

Poobalan A, et al. Effects of weight loss in overweight/ obese individuals and long-term lipid outcomes – a systematic review. Obes Rev 2004; 5:43-50.

Ley SJ, et al. Long-term effects of a reduced fat diet intervention on cardiovascular disease risk factors in individuals with glucose intolerance. *Diabetes Res Clin Pract* 2004; 63:103–112.

Lovejoy JC, et al. Consumption of a controlled low-fat diet containing olestra for 9 months improves health risk factors in conjunction with weight loss in obese men: the Ole' Study. *Int J Obes Relat Metab Disord* 2003; 27:1242–1249.

Bergholm R, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilation in obese women with previous gestational diabetes. *Diabetes Care* 2003; 26:1667– 1672.

Melanson K, et al. Weight loss and total lipid profile changes in overweight women consuming beef or chicken as the primary protein source. *Nutrition* 2003; 19:409–414.

Allison DB, et al. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. *Eur J Clin Nutr* 2003; 57:514–522.

Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. *Am J Cardiol* 2003; 91:961–964.

Reid R, et al. Dietary counseling for dyslipidemia in primary care: results of a randomized trial. *Can J Diet Pract Res* 2002; 63:169–175.

Boozer CN, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int *J Obes Relat Metab Disord* 2002; 26:593–604.

Parker B, et al. Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. *Diabetes Care* 2002; 25:425–430.

Delahanty LM, et al. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial. *J Am Diet Assoc* 2001; 101:1012–1023.

Ashley, JM, et al. Weight control in the physician's office. *Arch Intern Med* 2001; 161:1599–1604.

Shintani TT, et al. The Hawaii Diet: ad libitum high carbohydrate, low fat multi-cultural diet for the reduction of chronic disease risk factors: obesity, hypertension, hypercholesterolemia, and hyperglycemia. *Hawaii Med J* 2001; 60:69–73.

Raeini-Sarjaz M, et al. Comparison of the effect of dietary fat restriction with that of energy restriction on human lipid metabolism. *Am J Clin Nutr* 2001; 73:262– 267.

Manley SE, et al. Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins. *Diabetes Med* 2000; 17:518–523.

Cordero-MacIntyre ZR, et al. Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. *J Am Coll Nutr* 2000; 19:275–284.

Noakes M, Clifton PM. Weight loss and plasma lipids. *Curr Opin Lipidol* 2000; 11:65–70.

Purnell JQ, et al. Effect of weight loss with reduction of intraabdominal fat on lipid metabolism in older men. *J Clin Endocrinol Metab* 2000; 85:977–982.

Zambon A, et al. Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women. *J Intern Med* 1999; 246:191–201.

Di Buono M, et al. Weight loss due to energy restric-

tion suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. *J Nutr* 1999; 129:1545–1548.

Herbert JR, et al. A dietitian-delivered group nutrition program leads to reductions in dietary fat, serum cholesterol, and body weight: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *J Am Diet Assoc* 1999; 99:544–552.

Yu-Poth S, et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999; 69:632–646.

Bray GA, et al. Sibutramine produces dose-related weight loss. *Obes Res* 1999; 7:189–198.

Wadden TA, Anderson DA, Foster GD. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. *Obes Res* 1999; 7:170–178.

Turley ML, et al. The effect of a low-fat, high-carbohydrate diet on sesrum high density lipoprotein cholesterol and triglyceride. *Eur J Clin Nutr* 1998; 52:728–732.

Butowski PF, Winder AF. Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolemia. Data from the U.K. Lipid Clinics Programme. *Eur Heart J* 1998; 19:1328–1333.

Stefanick ML, et al. Effects of diet and exercise in men and postmenopausal women with low level HDL cholesterol and high levels of LDL cholesterol. *N Engl J Med* 1998; 339:12–20.

St Jeor ST, et al. A classification system to evaluate weight maintainers, gainers, and losers. *J Am Diet Assoc* 1997; 97:481–488.

Muls E, et al. Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates. *Int J Obes Relat Metab Disord* 1997; 21:155–158.

McCarron DA, et al. Nutritional management of cardiovascular risk factors. A randomized clinical trial. *Arch Intern Med* 1997; 157:169–177.

Fox AA, et al. Effects of diet and exercise on common cardiovascular disease risk factors in moderately obese older women. *Am J Clin Nutr* 1996; 63:225–233.

Pascale RW, et al. Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. *Diabetes Care* 1995; 18:1241–1248.

Schaefer EJ, et al. Body weight and low-density lipoprotein cholesterol changes after consumption of a lowfat ad libitum diet. *JAMA* 1995; 274:1450–1455.

Andersen RE, et al. Relation of weight loss to changes in serum lipids and lipoproteins in obese women. *Am J Clin Nutr* 1995; 62:350–357.

Wing RR, Jeffery RW. Effect of modest weight loss on changes in cardiovascular risk factors; are there difference between men and women or between weight loss and maintenance? *Int J Obes Relat Metab Disord* 1995; 19:67–73.

Svendsen OL, Hassager C, Christiansen C. Six months' follow-up on exercise added to a short-term diet in overweight postmenopausal women—effects on body composition, resting metabolic rate, cardiovascular risk factors and bone. *Int J Obes Relat Metab Disord* 1994; 18:692–698.

Svendsen OL, Hassager C, Christiansen C. Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. *Am J Med* 1993; 95:131–140.

Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr* 1992; 56:320–328.

Wolever TM, et al. Beneficial effect of low-glycemic index diet in overweight NIDDM subjects. *Diabetes Care* 1992; 15:562–564.

Anderson JW, Brinkman VL, Hamilton CC. Weight loss and 2-year follow-up for 80 morbidly obese patients treated with intensive very-low-calorie diet and an education program. *Am J Clin Nutr* 1992; 56:244S–246S.

Williams PT, et al. Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men. *Arteriosclerosis* 1989; 9:623–632.

Wood PD, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. *N Engl J Med* 1988; 319:1173–1179.

Hagan RD, et al. The effects of aerobic conditioning and/or caloric restriction in overweight men and women. *Med Sci Sports Exerc* 1986; 18:87–94.

Walsh DE, Yaghoubian V. Effect of glucomannan on obese patients: a clinical study. *Int J Obes* 1984; 8:289–293.